AROMATIC HETEROCYCLIC CARBOXYLIC ACID AMIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Abstract: Heteroaryl carboxamides of formula (I) and their pharmaceutically acceptable salts are new: where A is 3-5C alkylene gp.; X is (i) or (ii) Het is a gp. of formula (II) or (III): Y is GH or N; R1 is OH, 1-6C alkoxy or mercapto; R2 is H, halogen, 1-6C alkoxy, 1-6C alkyl, nitro or cyano; R3 is 1-6C alkyl; when Y is N, then R2 is on the 7-position of the ring. Preferred are (I) where A is tetramethylene; Het is 7-(1-4C alkyl) 4-hydroxy-1,8- napthyridin-3-yl or 6-(1-4C alkyl) -2-hydroxy -3-pyridinyl or is 3-quinolinyl 4-substd. by OH, 1-4C alkoxy or SH and opt. substd. on the carbocyclic rib by OH, 1-4C alkyl, 1-4C alkoxy or CN. N-(4-(4-diphenyl methylene-1- piperidinyl) butyl)-4- hydroxy-7-methyl- 1,8napthyridine- 3-carboxamide.

Description: The present invention relates to novel and useful heteroarylcarboxamide derivatives which have an antiallergic activity based on enzyme, especially 5-lipoxygenase, inhibitory activity. GB-A-1433774 and US-A-3943141 disclose 1,4-dihydro-4-oxo-N(1H-tetrazol-5-yl)-3- quinolinecarboxamide derivatives and 1,4-dihydro-4-oxo-N-(1H-tetrazol-5-yl)-1,8-naphthyridine-3-carboxamide derivatives, respectively, as useful antiallergic agents. DE-A-3242344 discloses that alkylenediamine derivatives such as N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]-propyl]-2-hydroxy-6-methylpyridine-3-carboxamide are useful for treatment of sinus tachycardia and ischemic heart diseases. EP-A-0113226 discloses certain benzhydrylpiperazine derivatives having antiallergic activities. US-A-3806526 discloses certain 1-aroylalkyl-4-diphenylmethylpiperidines as antihistamines, antiallergy agents and bronchodilators. The mechanism of the development of allergic diseases such as bronchial asthma and allergic rhinitis has been generally thought to be as follows. In genetically specific individuals who are exposed to allergens such as pollen or mite s, B-lymphocytes produce antigen-specific IgE in cooperation with macrophages and T-lymphocyte. The antigen-specific IgE binds to IgE receptors on the membrane of mast cells or basophiles. The bridging of IgE molecules by the re-invading antigen triggers a change of structure in the cell membrane, an incremental change in membrane fluidity and the activation of various enzymes (including 5-lipoxygenase). Consequently, chemical mediators such as leukotrienes C₄, D₄, E₄ and B₄, histamine and prostaglandins are released from these cells, and cause the syndromes in allergic disease. Among these chemical mediators, leukotrienes C₄, D₄ and E₄ cause strongly the contraction of bronchial smooth muscle [P. Hedqvist et al., Acta Physiol. Scand., 110 , 331 (1980)], increased vascular permeability [A. Ueno et al., Prostaglandins, 21 , 637 (1981)], and secretion of mucus [S. J. Coles et al., Prostaglandins, 25 , 155 (1983)], and leukotriene B₄ does leukocyte emigration [A. W. Ford-Hutchinson et al., Nature, 286 , 264 (1980)], playing an important role in the development of allergic diseases. Compounds which inhibit the biosynthesis and release of leukotrienes or inhibit the binding of leukotrienes to their receptors may be useful for the prophylaxis or treatment of allergic diseases. 5-Lipoxygenase is an enzyme which catalyzes an early step in the biosynthesis of leukotrienes, that is, the conversion of arachidonic acid into 5-hydroperoxyeicosatetraenoic acid. We have conducted intensive studies in an attempt to find a compound which can inhibit the 5-lipoxygenase and, as a result, have found that this can be achieved by an aromatic heterocyclic carboxylic acid derivative represented by the following formula (I). The present invention provides a heteroarylcarboxamide derivative of the formula (I): wherein A means an alkylene group having 3 to 5 carbon atoms, X means NCHPh₂ or C=CPh₂ in which Ph means phenyl and means the formulas: in which Y is a nitrogen atom or =CH-, R₁ is hydroxy or mercapto, R₂ is a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, nitro or cyano, R₃ is an alkyl group having 1 to 6 carbon atoms, provided that R₂ is attached at the 7-position when Y is a nitrogen atom,or a physiologically acceptable salt thereof, a process for the preparation thereof and a pharmaceutical composition containing the same as an active ingredient. The physiologically acceptable salts of the compounds represented by the formulae (I) and (Ib) include, for example, inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate and phosphate, and organic acid salts such as oxalate, maleate, fumarate, lactate, malate, citrate, tartrate, benzoate and methanesulfonate. Since the compounds of the present invention may exist in the form of hydrates or solvates these hydrates and solvates are also included in the present invention. Since the compounds of the present invention may exist in the form of tautomers represented by the following formula (I'), these tautomers are also included in the compound of the present invention. wherein A and X mean the same as defined above, means a group of the formula: in which Y, R₂ and R₃ are the same as defined above, and Z is an oxygen atom or sulfur atom. In the following description, the structure and nomenclature of the compounds of the present invention are indicated with reference to the formula (I). The terms in the specification are explained as follows. The alkylene group, alkyl group and alkoxy group may be either a straight chain or a branched chain. The "alkylene group" includes, for example, trimethylene, tetramethylene and pentamethylene, preferably tetramethylene. The "alkoxy group" includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy and pentyloxy, preferably those having 1 to 4 carbon atoms. The "halogen atom" is selected from fluorine, chlorine, bromine and iodine, preferably from fluorine, chlorine and bromine. The "alkyl group" includes, for example, methyl, ethyl, propyl, isopropyl, butyl and pentyl, preferably those having 1 to 4 carbon atoms. Preferable compounds of the present invention include those of the formula (I) wherein A is tetramethylene and physiologically acceptable salts thereof. More preferable compounds of the present invention include the compounds of the formula (Ia): wherein X is the same as defined above, means a group of the formula: in which R 2a and R 3a are each an alkyl group having 1 to 4 carbon atoms, respectively, and physiologically acceptable salts thereof. Other more preferable compounds of the present invention include the compounds of the formula (Ib): wherein X and R₁ are the same as defined above, R 2b is a hydrogen atom, hydroxy, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms or cyano, and physiologically acceptable salts thereof. Particularly preferable compounds of the present invention include the following compounds and physiologically acceptable salts thereof. N-[4-(4-Diphenylmethylene-1-piperidyl)butyl]-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxamide, N-[4-(4-Diphenylmethyl-1-piperazinyl)butyl]-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxamide, N-[4-(4-Diphenylmethyl-1-piperazinyl)butyl]-4-hydroxy-8-methoxyquinoline-3-carboxamide, and N-[4-(4-Diphenylmethyl-1-piperazinyl)butyl]-2-hydroxy-6-isopropylpyridine-3-carboxamide The compounds of the present invention can be prepared, for example, by the following process. The compound of the formula (II): wherein means the same as defined above, or a reactive derivative thereof is reacted with an amine of the formula (III): wherein A and X mean the same as defined above to prepare the compounds of the formula (I). The reactive derivatives of the compounds of the formula (II) include, for example, activated esters, acid anhydrides, acid halides (especially acid chloride) and lower alkyl esters. Suitable examples of the activated esters include p-nitrophenyl ester, 2,4,5-trichlorophenyl ester, pentachlorophenyl ester, cyanomethyl ester, N-hydroxysuccinimide ester, N-hydroxyphthalimide ester, 1-hydroxybenzotriazole ester, N-hydroxy-5-norbornene-2,3-dicarboximide ester, N-hydroxypiperidine ester, 8-hydroxyquinoline ester, 2-hydroxyphenyl ester, 2-hydroxy-4,5-dichlorophenyl ester, 2-hydroxypyridine ester and 2-pyridylthiol ester. The acid anhydrides include both symmetric acid anhydrides and mixed acid anhydrides. Suitable examples of the mixed acid anhydrides include those with alkyl chloroformates such as ethyl chloroformate or isobutyl chloroformate, with aralkyl chloroformates such as benzyl chloroformate, with aryl chloroformates such as phenyl chloroformate or with alkanoic acids such as isovaleric acid or pivalic acid. When the compound of the formula (II) is employed as it is, the compound (II) can be reacted with the compound (III) in the presence of a condensing agent such as dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N,N'-carbonyldiimidazole or 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroxyquinoline. When dicyclohexylcarbodiimide or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride is employed as the condensing agent, the reaction may be conducted with addition of, for example, N-hydroxysuccinimide, 1-hydroxybenzotriazole, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine or N-hydroxy-5-norbornene-2,3-dicarboximide. The reaction between the compound of the formula (II) or the reactive derivative thereof and the amine of the formula (III) is carried out without a solvent or in a suitable solvent. Although the choice of any solvent employed would vary depending, for example, on the kind of the starting compounds, the solvent used in the reaction of the present invention includes, for example, aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran and dioxane; halogenated hydrocarbons such as methylene chloride and chloroform; ethyl acetate, acetonitrile, dimethylformamide, dimethyl sulfoxide and water. These solvents are employed alone or in combination of two or more thereof. The reaction is optionally carried out in the presence of a base. The base includes alkali metal bicarbonates such as sodium bicarbonate or potassium bicarbonate, alkali metal carbonates such as sodium carbonate or potassium carbonate, or organic bases such as triethylamine, tributylamine, diisopropylethylamine, or N-methylmorpholine. An excess amount of the amines of the formula (III) may also be employed as the base. The reaction temperature usually ranges from about -40°C to about 200°C, preferably from about -20°C to about 150°C, though it may vary depending on, for example, the kinds of the starting compounds. The starting compounds (II) can be prepared, for example, by the processes as described in J. Am. Chem. Soc., 70 , 3348 (1948) and ibid., 68 , 1264 (1946). The starting compounds (III) can be prepared, for example, by the process as described in the Reference Example, given later. The compounds prepared by the above process can be isolated and purified by the conventional methods such as chromatography, recrystallization or reprecipitation. The compounds of the formula (I) are obtained in the form of a free base or salt, a hydrate or a solvate depending, for example, on the conditions of the reaction and the treatment. The salt can be converted into a free base by a conventional procedure, for example, by treating with a base such as an alkali metal carbonate. On the other hand, the free base can be converted into a salt by treating with any of various acids in accordance with conventional procedure. In the following Experiments, the pharmacological activities of the compounds of the present invention are illustrated by pharmacological tests on typical compounds of the present invention and ketotifen fumarate which is a commercially available antiallergic agent. Experiment 1 Inhibitory effect on 5-lipoxygenase activity (antiallergic activity in vitro ) This experiment was carried out by the method of Miyamoto and Obata ["Perspectives in Prostaglandin Research", ed. by Y. Shiokawa et al., Excerpta Medica, Amsterdam-Oxford-Princeton, 1983, p.78] with minor modifications. A cytosol fraction of peritoneal exudate cell from male Hartley guinea pig (weighing 400 to 700 g) was used as 5-lipoxygenase. As a standard reaction solution, a mixture of 50 mM potassium phosphate buffer (pH 7.4), 1 mM calcium chloride, 1 mM glutathione, 1 mM adenosine triphosphate, 10 µM indomethacin and the enzyme was used. To the reaction solution was added 0.02 µCi of [1-¹⁴C] arachidonic acid and the mixture was incubated at 30°C for 5 minutes, followed by adding 0.6 ml of a cold solution comprising diethyl ether - methanol - 0.2 M citric acid (30 : 4 : 1) to terminate the reaction. The organic layer (300 µl) was subjected to a thin layer chromatography plate on silica gel 60 F₂₅₄ (E. Merck, West Germany) and, after developing, a radioactivity was measured by means of radiochromatogram scanner (Packard, U.S.A.). 5-Lipoxygenase activity was calculated by the following equation. 5-HETE: 5-hydroxyeicosatetraenoic acid The inhibitory rate was calculated from 5-lipoxygenase activities without vs. with the test compound (10⁻⁵ M). The results are shown in Table 1 in terms of mean value of 3 to 6 experiments. 5-Lipoxygenase Inhibitory Activity Test Comp. 5-Lipoxygenase inhibition (%) Test Comp. 5-Lipoxygenase inhibition (%) 1 96.8 11 83.7 2 79.6 13 93.7 3 91.3 14 93.0 4 95.4 15 90.6 16 95.3 5 75.1 17 93.2 6 92.1 18 92.8 84.7 19 94.8 7 93.3 20 67.9 8 88.3 Ketotifen fumarate 11.5 As is clear from Table 1, the compounds of the present invention inhibited strongly 5-lipoxygenase activity. On the other hand, ketotifen fumarate did not show any significant inhibitory activity even at the concentration of 10⁻⁴ M. Experiment 2 Inhibitory effect on passive cutaneous anaphylaxis (PCA) (antiallergic activity in vivo ) This experiment was carried out by the method of Perper et al., [J. Pharmacol. Exp. Ther., 193 , 594 (1975)]. Male Wistar rats (weighing 130 to 190 g) were injected with a dilute solution (0.1 ml) of mouse antiserum to egg albumin, which was prepared by the method of Levine et al. [Int. Arch. Allergy Appl. Immunol., 39 , 156 (1970)], in two sites of the shaved ventral skin. Forty-eight hours later, 0.5% Evan's blue solution (1 ml) containing 2 mg of egg albumin was intravenously injected to tail vein of the animal. Thirty minutes after the dye injection, abdominal skin was peeled off and the area of the blueing lesions was measured. In each rat, a mean value of the two lesions was regarded as the response of the rat. The test compounds in a dose of 20 mg/kg, dissolved or suspended in a 0.5% aqueous tragacanth solution, were orally administered 1 hour prior to the dye injection. Table 2 shows an inhibitory rate obtained by comparing the response of the rats given each test compound with that of the rats given only a 0.5% aqueous tragacanth solution (control group). PCA Inhibitory Activity Test comp. PCA inhibition (%) Test comp. PCA inhibition (%) 1 88.3 5 93.0 2 80.7 9 84.8 3 56.0 Ketotifen fumarate 54.7 As is clear from Table 2, the compounds of the present invention showed a PCA inhibitory activity equivalent to or more potent than that of ketotifen fumarate. Experiment 3 Acute toxicity Five male ddY mice weighing 25 to 29 g were used in each group. A fixed amount of the compound of Example 1, 3 or 5 suspended in a 0.5% aqueous tragacanth solution was orally administered and the animals were observed for 7 days after the administration to see whether any had died. As a result, none had died after the administration of 1000 mg/kg of each compound of Example 1, 3 or 5. Therefore, the dose for showing an acute toxicity of these compounds is much higher than that for showing the antiallergic activity. Since the compounds of the formula (I) and physiologically acceptable salts thereof show an excellent antiallergic activity mainly based on the 5-lipoxygenase inhibitory activity with less toxicity, they can be used as an antiallergic agent for the prophylaxis and treatment of allergic diseases such as bronchial asthma, allergic rhinitis, urticaria, atopic dermatitis, eczema and allergic ophthalmia. The compounds of the formula (I) and physiologically acceptable salts thereof may be administered by any route of oral administration, parenteral administration, intra-rectal administration and topical administration, preferably by oral or topical administration. A dose of the compounds of the formula (I) or salts thereof usually ranges from 0.005 to 40 mg/kg/day, preferably from 0.01 to 5 mg/kg/day, though it may vary, for example, depending on the type of compound, administration route, severity of disease or age of the patient. The compounds of the formula (I) or salts thereof are usually administered in the form of a pharmaceutical composition in admixture with pharmaceutically acceptable carriers. The pharmaceutically acceptable carriers include substances which are conventionally employed in the field of the pharmaceutical preparations and do not react with the compound of the formula (I) or the salts thereof. Suitable examples of the carriers are lactose, glucose, mannitol, dextrin, cyclodextrin, starches, sucrose, magnesium aluminosilicate tetrahydrate, synthetic aluminum silicate, microcrystalline cellulose, sodium carboxymethylcellulose, hydroxypropyl starch, calcium carboxymethylcellulose, ion exchange resin, methylcellulose, gelatin, acacia, hydroxypropyl cellulose, substituted hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, light anhydrous silicic acid, magnesium stearate, talc, tragacanth, bentonite, veegum, carboxyvinyl polymer, titanium dioxide, sorbitan fatty acid esters, sodium lauryl sulfate, glycerin, glycerin fatty acid esters, anhydrous lanolin, glycero-gelatin, polysorbate, macrogol, vegetable oils, waxes, liquid paraffin, white petrolatum, fluorocarbons, nonionic surfactants, propylene glycol and water. The pharmaceutical composition may be in the dosage form, for example, of tablets, capsules, granules, powders, syrups, suspensions, suppositories, ointments, creams, gels, adhesive preparations, inhalants and injections. These compositions can be prepared by a conventional method. The liquid preparations may be in a form which is dissolved or suspended in an appropriate solvent such as water or others when used. The tablets and granules may be coated with a conventional coating material in a usual manner. The injections are usually prepared by dissolving the physiologically acceptable salts of the compounds of the formula (I) in water, but occasionally in physiological saline or a glucose solution, to which buffering agents or preservatives are optionally added. These compositions may contain the compounds of the formula (I) or the physiologically acceptable salts thereof at a ratio of not less than 0.2 %, preferably in the range of from 0.5 to 70 %. These compositions may also contain other ingredients useful for the treatment. Embodiments of the present invention are illustrated by the following Examples and Reference Example. The identification of the compounds was carried out by elemental analysis, mass spectrum, IR spectrum, NMR spectrum and the like. Example 1 Preparation of N-[4-(4-diphenylmethylene-1-piperidyl)butyl]-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxamide·1/4 hydrate: To 4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylic acid (0.77 g) is added dry chloroform (30 ml) and thereto is added triethylamine (0.76 g) with stirring at room temperature. The solution is kept at below -5°C and thereto is added dropwise ethyl chloroformate (0.81 g), and the mixture is stirred for 2 hours. After 4-(4-diphenylmethylene-1-piperidyl)butylamine (1.2 g) is added gradually, the mixture is stirred at below -5°C for 1 hour and further at room temperature overnight. After insoluble substances are filtered off, the filtrate is concentrated and the residue is subjected to silica gel column chromatography, followed by elution with chloroform - methanol (40 : 1) to give oils. The crystallized product is taken and recrystallized from toluene to give the desired compound (0.6 g). m.p. 168 to 170°C Example 2 Preparation of N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxamide·1/2 hydrate: To 4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylic acid (0.63 g) is added dry chloroform (30 ml) and thereto is added triethylamine (0.63 g) with stirring at room temperature. The solution is kept at below -5°C and thereto is added dropwise ethyl chloroformate (0.67 g), and the mixture is stirred for 2 hours. After 4-(4-diphenylmethyl-1-piperazinyl)butylamine (1 g) is added gradually, the mixture is stirred at below -5°C for 1 hour and further at room temperature overnight. After insoluble substances are filtered off, the filtrate is concentrated and the residue is subjected to silica gel column chromatography, followed by elution with chloroform - methanol (40 : 1) to give oils. The crystallized product is taken and recrystallized from acetonitrile to give the desired compound (0.3 g). m.p. 202 to 205°C Example 3 Preparation of N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-4-hydroxy-8-methoxyquinoline-3-carboxamide: To 4-hydroxy-8-methoxyquinoline-3-carboxylic acid (1.0 g) is added dry pyridine (40 ml) and the mixture is heated at 80°C. Thereto is added p-nitrophenyl trifluoroacetate (2.6 g) and the mixture is stirred at the same temperature for 1 hour. After the mixture is allowed to cool, the precipitated crystals are filtered and washed with diethyl ether to give an activated ester. Thereto is added dry dimethylformamide (30 ml), followed by adding 4-(4-diphenylmethyl-1-piperazinyl)butylamine (3.5 g) with stirring at room temperature. After the reaction mixture is stirred for 1 hour, the dimethylformamide is distilled off. Chloroform is added to the residue and the chloroform solution is washed with water, dried over anhydrous magnesium sulfate and then concentrated. The residue is subjected to silica gel column chromatography, followed by elution with chloroform - triethylamine (50 : 1). The obtained crystals are recrystallized from ethanol to give the desired compound (1.02 g). m.p. 209 to 212°C. Example 4 Preparation of N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-4,5-dihydroxyquinoline-3-carboxamide: N,N'-Carbonyldiimidazole (1.2 g) is added to a solution of 4,5-dihydroxyquinoline-3-carboxylic acid (0.7 g), which is prepared according to the method described in JP-A- 65874/1981, in dry dimethyl sulfoxide (30 ml) and the mixture is stirred at room temperature for 30 minutes. 4-(4-Diphenylmethy1-1-piperazinyl)butylamine (2.2 g) is added to the reaction mixture and the mixture is stirred at room temperature for 6 hours, and thereto is added water (about 200 ml), and the mixture is extracted with chloroform. The organic layer is dried over anhydrous magnesium sulfate and the solvent is distilled off. The residue is subjected to silica gel column chromatography, followed by elution with chloroform - methanol (30 : 1). The obtained crystals are recrystallized from isopropyl alcohol to give the desired compound (0.72 g). m.p. 215 to 218°C Example 5 Preparation of N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-2-hydroxy-6-isopropylpyridine-3-carboxamide: Dry pyridine (30 ml) is added to 2-hydroxy-6-isopropylpyridine-3-carboxylic acid (1.0 g), prepared according to the method described in J. Am. Chem. Soc., 73 , 1368 (1951), and the mixture is heated at 80°C. Thereto is added p-nitrophenyl trifluoroacetate (2.9 g) and the mixture is stirred at 80°C for 1 hour. The mixture is allowed to cool and the precipitated crystals are filtered and washed with diethyl ether to give an activated ester. Dry dimethylformamide (30 ml) is added thereto and 4-(4-diphenylmethyl-1-piperazinyl)butylamine (1.8 g) is further added with stirring at room temperature. After stirring the reaction mixture for 1 hour, dimethylformamide is distilled off. Chloroform is added to the residue and the chloroform solution is washed with water, dried over anhydrous magnesium sulfate and then concentrated. The residue is subjected to silica gel column chromatography, followed by elution with chloroform - methanol (30 : 1). The obtained crystals are recrystallized from acetonitrile to give the desired compound (1.6 g). m.p. 184.5 to 185.5°C Example 6 Preparation of N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-5-cyano-4-hydroxyquinoline-3-carboxamide and N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-7-cyano-4-hydroxyquinoline-3-carboxamide: In accordance with the method described in J. Med. Chem., 20 , 1001 (1977), a 1:1 mixture of 5-cyano-4-hydroxyquinoline-3-carboxylic acid and 7-cyano-4-hydroxyquinoline-3-carboxylic acid (confirmed by NMR spectrum) is prepared from m-cyanoaniline. In the same manner as described in Example 1, the above mixture and 4-(4-diphenylmethyl-1-piperazinyl)butylamine are reacted in place of 4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylic acid and 4-(4-diphenylmethylene-1-piperidyl)butylamine in Example 1 respectively. Insoluble substances are filtered off and then the filtrate is concentrated. The residue is subjected to silica gel column chromatogaphy, followed by elution with chloroform - methanol (30 : 1). From the first eluted fraction there is obtained N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-7-cyano-4-hydroxyquinoline-3-carboxamide, which is recrystallized from acetonitrile to give a product of m.p. 223 to 225°C. From the subsequent fraction there is obtained N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-5-cyano-4-hydroxyquinoline-3-carboxamide, which is recrystallized from acetonitrile to give a product of m.p. 232 to 234°C (dec.). Example 7 Preparation of N-[4-(4-diphenylmethylene-1-piperidyl)butyl]-4-hydroxy-8-methoxyquinoline-3-carboxamide·fumarate: The procedures of Example 1 are repeated except that 4-hydroxy-8-methoxyquinoline-3-carboxylic acid is employed in place of 4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylic acid to give N-[4-(4-diphenylmethylene-1-piperidyl)butyl]-4-hydroxy-8-methoxyquinoline-3-carboxamide, which is converted into fumarate in a usual manner. The fumarate is recrystallized from ethanol - diethyl ether to give the desired compound. m.p. 232 to 236°C. Example 8 Preparation of N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-4-mercapto-7-methyl-1,8-naphthyridine-3-carboxamide·fumarate·1/2 hydrate: The procedures of Example 1 are repeated except that 4-mercapto-7-methyl-1,8-naphthyridine-3-carboxylic acid, prepared according to the method described in Farmaco. Ed. Sci., 28 , 722 (1973), and 4-(4-diphenylmethyl-1-piperazinyl)butylamine are employed in place of 4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylic acid and 4-(4-diphenylmethylene-1-piperidyl)butylamine to give N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-4-mercapto-7-methyl-1,8-naphthyridine-3-carboxamide as oils, which is converted into fumarate in a conventional manner. The fumarate is recrystallized from ethanol - water to give the desired compound. m.p. 209 to 212°C Example 9 Preparation of N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-2-hydroxy-6-methylpyridine-3-carboxamide: The procedures of Example 5 are repeated except that 2-hydroxy-6-methylpyridine-3-carboxylic acid, prepared in accordance with the method described in J. Org. Chem., 37 , 1145 (1972), is employed in place of 2-hydroxy-6-isopropylpyridine-3-carboxylic acid to give the desired compound. m.p. 213 to 214°C (recrystallized from toluene) Example 10 Preparation of N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-4-hydroxy-7-methoxy-1,8-naphthyridine-3-carboxamide·1/4 hydrate: The procedures of Example 2 are repeated except that 4-hydroxy-7-methoxy-1,8-naphthyridine-3-carboxylic acid is employed in place of 4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxylic acid to give the desired compound. m.p. 205 to 208°C (recrystallized from acetonitrile) Examples 11 to 22 Employing the corresponding starting materials, the procedures of Examples 1 to 5 are repeated to give the compounds shown in Table 3. In Table 3, the following abbreviations are used to simplify the description. AN : Acetonitrile CH : Chloroform E : Diethyl ether IA : Isopropyl alcohol M : Methanol T : Toluene The starting materials in Examples 1 and 7 are prepared by the method described in the following Reference Example. Reference Example Preparation of 4-(4-diphenylmethylene-1-piperidyl)butylamine: 4-Diphenylmethylenepiperidine (9.5 g), N-(4-bromobutyl)phthalimide (16 g), sodium iodide (8 g) and potassium carbonate (9 g) are added to methyl ethyl ketone (200 ml) and the mixture is refluxed with stirring for 4 hours. The reaction mixture is concentrated and water (150 ml) is added to the residue. The aqueous layer is extracted three times with chloroform (each 100 ml). The combined extracts are dried over anhydrous magnesium sulfate and then concentrated. The residue is subjected to silica gel column chromatography, followed by elution with chloroform to give N-[4-(4-diphenylmethylene-1-piperidyl)butyl]phthalimide (13.7 g). The obtained phthalimide compound (13.7 g) and hydrazine monohydrate (2.5 g) are added to ethanol (34 ml) and the mixture is refluxed with stirring for 2 hours. After cooling, a small amount of water is added to the reaction mixture and the solvent is distilled off under reduced pressure. Chloroform (200 ml) is added to the residue and the insoluble substances are filtered off and washed twice with chloroform (each 50 ml). The filtrate and the washings are combined together, washed with water, dried over anhydrous magnesium sulfate and concentrated to give the desired compound (12 g). Mass spectrum m/z: 320 (M⁺) Example 23 per 1000 tablets N-[4-(4-Diphenylmethylene-1-piperidyl)butyl]-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxamide·1/4 hydrate 1 g Corn starch 29 g Lactose 55 g Microcrystalline cellulose 11 g Hydroxypropyl cellulose 3 g Light anhydrous silicic acid 0.5 g Magnesium stearate 0.5 g In accordance with a conventional method, the above components are blended, granulated and compressed to prepare 1000 tablets of each 100 mg. Example 24 per 1000 capsules N-[4-(4-Diphenylmethyl-1-piperazinyl)butyl]-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxamide·1/2 hydrate 1 g Corn starch 107 g Lactose 65 g Hydroxypropyl cellulose 5 g Light anhydrous silicic acid 1 g Magnesium stearate 1 g In accordance with a conventional method, the above components are blended, granulated and filled in 1000 capsules to prepare capsules of each 180 mg. Examples 25 ointments N-[4-(4-Diphenylmethyl-1-piperazinyl)butyl]-2-hydroxy-6-isopropylpyridine-3-carboxamide 5 g Liquid paraffin 10 g White petrolatum 85 g In accordance with a conventional method, the above components are blended to prepare 5% ointments. Industrial Applicability As mentioned above, the compounds of the formula (I) of the present invention and physiologically acceptable salts thereof are useful for the prophylaxis and treatment of allergic diseases of mammals including human as an antiallergic agent.

Claims: A compound of the formula (I): wherein A is an alkylene group having 3 to 5 carbon atoms, X is NCHPh₂ or C=CPh₂ in which Ph is phenyl and is a group of the formula: in which Y is a nitrogen atom or =CH-, R₁ is hydroxy or mercapto, R₂ is a hydrogen atom, a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, nitro or cyano, R₃ is an alkyl group having 1 to 6 carbon atoms, provided that R₂ is attached at the 7-position when Y is a nitrogen atom, or a physiologically acceptable salt thereof. The compound according to claim 1 wherein A is tetramethylene, or a physiologically acceptable salt thereof. The compound according to claim 1 which is represented by the formula (Ia): wherein X is as defined in claim 1, is a group of the formula: in which R 2a and R 3a are each an alkyl group having 1 to 4 carbon atoms, or a physiologically acceptable salt thereof. A compound of the formula (Ib): wherein X and R₁ are as defined in claim 1, R 2b is a hydrogen atom, hydroxy, an alkyl group having 1 to 4 carbon atoms, an alkoxy group having 1 to 4 carbon atoms or cyano, or a physiologically acceptable salt thereof. The compound according to claim 3, which is N-[4-(4-diphenylmethylene-1-piperidyl)butyl]-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxamide or a physiologically acceptable salt thereof. The compound according to claim 3, which is N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-4-hydroxy-7-methyl-1,8-naphthyridine-3-carboxamide, or a physiologically acceptable salt thereof. The compound according to claim 4, which is N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-4-hydroxy-8-methoxyquinoline-3-carboxamide, or a physiologically acceptable salt thereof. The compound according to claim 3, which is N-[4-(4-diphenylmethyl-1-piperazinyl)butyl]-2-hydroxy-6-isopropylpyridine-3-carboxamide, or a physiologically acceptable salt thereof. A process for preparing a compound of the formula (I): wherein A, X and are as defined in claim 1, or a physiologically acceptable salt thereof, which comprises reacting a compound of the formula (II): wherein is as defined in claim 1, or a reactive derivative thereof, with an amine of the formula (III): wherein A and X are as defined in claim 1. A pharmaceutical composition containing the compound as set forth in any one of claims 1 to 8 or a physiologically acceptable salt thereof and a pharmaceutical carrier.

Inventors: ISHII, KATSUMI, KON, TATSUYA, NAKAMURA, HIDEO, NISHIKAWA, YOSHINORI, SHINDO, TOKUHIKO, UNO, HITOSHI
Applicants: DAINIPPON PHARMACEUTICAL CO., LTD.
Application year: 1988
Main classification: C07D401
IPC codes: A61K31, C07D413, A61P27, A61P43, C07D261, C07D409, C07D217, C07D471, C07D237, C07D207, C07D401, C07D215, C07D241, C07D307, C07D495, C07D263, A61P11, C07D213, C07D417, C07D233, A61P37, C07D235, C07D239